15 results about "Bifidobacterium adolescentis" patented technology

The application belongs to the technical field of microorganisms and particularly relates to a Bifidobacterium adolescentis beneficial to skin, a derivative of the Bifidobacterium adolescentis and application of the Bifidobacterium adolescentis and the derivative. The derivative of the Bifidobacterium adolescentis has significant antioxidant and anti-inflammatory effects, can inhibit pathogenic bacteria of acne and other common skin infections such as Propionibacterium acnes, Staphylococcus aureus and Malassezia furfur, can eliminate pathogenic bacteria, can inhibit skin lipid accumulation, can avoid follicle blockage, and can improve skin problems in multiple directions, especially acne skin problems.

This invention relates to the field of probiotic screening and application technology, specifically to a Bifidobacterium adolescentis HC2916 that inhibits melanin synthesis, its microbial preparations, and applications. Bifidobacterium adolescentis HC2916 was deposited on May 16, 2023, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 27352. This strain exhibits excellent antioxidant capacity, capable of scavenging various free radicals and inhibiting lipid peroxidation. Furthermore, its fermentation supernatant and lysate significantly downregulate the protein and mRNA expression of MITF, a core factor in melanin production signaling, and inhibit the expression of its downstream key enzymes TYRP1 and TYRP2. This effectively suppresses UVA-induced increases in melanin content in skin keratinocytes, demonstrating promising application prospects in the field of skin whitening.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The application discloses a kind of composite microecological preparation and preparation method and application, belong to microbial technical field.The composite microecological preparation is core-shell structure, the core-shell structure is divided into inside and shell layer, inside includes Bifidobacterium adolescentis, shell layer includes metal polyphenol network and ficoll polysaccharide;The metal polyphenol network includes the complex coating formed by pterostilbene and calcium ion.The core is BA, the shell is made of FCPS, PTE, Ca 2+ Network composition, can protect Bifidobacterium adolescentis to reach intestine successfully and colonize, directly inhibit inflammatory response, and relieve CDI-induced mouse colitis and oxidative stress damage by regulating intestinal flora, indole and the generation of indole derivatives, solve the pain point that traditional microecological preparation probiotic survival rate is low, poor targeting, limited effect.

This invention discloses a biological agent for enhancing the immune response to hepatitis B vaccine using *Bifidobacterium adolescentis*, comprising: a preparation of *Bifidobacterium adolescentis* and a hepatitis B vaccine. The *Bifidobacterium adolescentis* preparation is a live *Bifidobacterium adolescentis* capsule. The live *Bifidobacterium adolescentis* capsule uses *Bifidobacterium adolescentis* live capsules from Lizhu Chang Le. The hepatitis B vaccine is a recombinant yeast hepatitis B vaccine. The recombinant yeast hepatitis B vaccine uses a recombinant hepatitis B vaccine from *Saccharomyces cerevisiae*. In high-responder populations receiving hepatitis B vaccine booster vaccination, the intestinal flora is rich in *Bifidobacterium adolescentis* 8 weeks post-vaccination. KEGG function analysis indicates that the intestinal flora function of high-responder populations is stronger than that of low / non-responder populations to hepatitis B vaccine. Bifidobacterium is positively correlated with various metabolic functions. Oral administration of *Bifidobacterium adolescentis* can enhance the immune response to hepatitis B vaccine.

The application discloses an adult depression intestinal microorganism marker and application thereof, and belongs to the field of biological medicine. The microorganism marker comprises one or more of the following: Clostridium aldrichii, Coprococcus comes, Klebsiella pneumoniae, Bifidobacterium adolescentis, Bacteroides vulgatus, Eubacterium eligens and Faecalibacterium prausnitzii. The application provides a product (such as a kit) comprising detection reagents for detecting the relative abundance of the microorganism marker. The product provided by the application has good feasibility and accuracy, and can effectively evaluate the risk of whether an adult has depression, thereby providing a new tool for clinical diagnosis.

The application discloses a fermentation medium for improving osmotic tolerance and culture density of Bifidobacterium adolescentis and application thereof. The special fermentation medium for Bifidobacterium adolescentis contains isomaltooligosaccharide and uracil. By using the fermentation medium to ferment and cultivate Bifidobacterium adolescentis, Bifidobacterium adolescentis with strong osmotic tolerance can be obtained, and the fermentation medium can effectively promote the propagation capacity of Bifidobacterium adolescentis, so that a larger amount of colonies can be expanded in unit area / volume, the culture density of Bifidobacterium adolescentis is greatly improved, and the industrial production value of Bifidobacterium adolescentis is improved.

The application discloses a fisetin-4'-O-alpha-D-glucopyranoside for resisting lung cancer and a preparation method and application thereof, and the preparation method comprises the following steps: taking sucrose as a glycosyl donor, taking fisetin as a glycosyl acceptor, and performing an enzymatic transglycosylation reaction under the catalysis of sucrose phosphorylase to direct the glucose group generated by decomposing the sucrose to be transferred to a hydroxyl group at a C4' position of the fisetin, so that a target product is obtained; and the sucrose phosphorylase is derived from Bifidobacterium adolescentis. The application retains the original core biological activities of the fisetin, such as antioxidation and anti-inflammation, provides high-quality raw materials for the application of the fisetin in the fields of innovative drug development for resisting lung cancer and preparation of medical intermediates, and expands the clinical transformation potential of fisetin compounds.

This invention relates to *Bifidobacterium adolescentis*, a composition containing it, and its application in preparing intestinal inflammation models, belonging to the field of molecular biology. To address the lack of existing research on the role of *Bifidobacterium adolescentis* and phenylalanine in early life immune regulation, this invention provides *Bifidobacterium adolescentis* SZBAD1096 (accession number GDMCC NO:67848), comprehensively revealing the molecular mechanism by which *Bifidobacterium adolescentis* SZBAD1096 mediates host intestinal immune damage through the phenylalanine metabolic pathway, and its application in preparing intestinal inflammation models. This provides important theoretical and experimental basis for accurately assessing the safety of *Bifidobacterium* strains and developing inflammatory intervention strategies targeting the intestinal microecology.

The present disclosure relates generally to probiotics for reducing pro-inflammatory cytokine release. In particular, the present disclosure provides a Bifidobacterium adolescentis that can reduce overall pro-inflammatory cytokines, such as interleukin-6 (IL-6), in a subject. The present disclosure provides a method for preventing, reducing, or ameliorating stress and / or anxiety symptoms in a subject in need thereof with a Bifidobacterium adolescentis strain (Bif038) deposited as DSM 29103.

The invention discloses a primer probe combination for detecting various bifidobacteria and application of the primer probe combination, and belongs to the field of molecular biological detection. The primer probe combination provided by the invention comprises a primer probe group for detecting bifidobacterium breve, a primer probe group for detecting bifidobacterium bifidum and a primer probe group for detecting bifidobacterium adolescentis. Based on the primer probe combination, the invention respectively develops a single PCR detection method and a triple PCR detection method for detecting the three bifidobacteria. Experimental results show that the detection method provided by the invention can be used for accurately detecting bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis. According to the invention, a foundation is laid for authenticity identification of products containing bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis, and a more convenient method is provided for detection of bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis.

The application discloses a high-osmotic-pressure-resistant Bifidobacterium adolescentis and application thereof, and belongs to the technical field of microorganisms. The application screens out a Bifidobacterium adolescentis CCFM1302, and the Bifidobacterium adolescentis CCFM1302 can be efficiently industrialized. The fermentation density of the strain cultured at 37 DEG C and constant pH 5.5 in a 5L three-in-one in-situ sterilization fermentation tank can reach (1.82+ / -0.08) x 10 10 CFU / mL, the viable bacterial number of bacterial powder after freeze-drying can reach (7.13+ / -0.80) x 10 11 CFU / g, and the freeze-drying survival rate can reach (67.87+ / -0.35) %. Therefore, the Bifidobacterium adolescentis CCFM1302 has a high application prospect in industrial production.

The application discloses an anti-inflammatory and anti-oxidative gallic acid glycoside as well as a preparation method and application thereof. The preparation method comprises the following steps: taking sucrose as a glucosyl donor, taking gallic acid as a glucosyl acceptor, and performing an enzymatic reaction under the catalysis of sucrose phosphorylase to transfer a glucosyl generated by the decomposition of sucrose to a C4 hydroxyl group of the gallic acid to obtain the gallic acid glycoside; and the sucrose phosphorylase is derived from Bifidobacterium adolescentis. In the application, sucrose is taken as a glucosyl donor, gallic acid is taken as a receptor, and a glucosyl generated by the hydrolysis of sucrose is accurately transferred to a C4 hydroxyl group of the gallic acid through a high-efficiency transglycosylation reaction, so that the conversion rate of a target product is significantly improved, and core technical support is provided for large-scale preparation.

This invention discloses a metabiotic prepared from a strain of *Bifidobacterium adolescentis* that promotes host collagen synthesis, belonging to the fields of microbial technology and pharmaceutical technology. The metabiotic of *Bifidobacterium adolescentis* CCFM1386 provided by this invention has a good effect on promoting host collagen synthesis, improving skin moisture and elasticity, and simultaneously enhancing skin's antioxidant capacity and maintaining collagen homeostasis. Specifically, in vitro, bacterial lysate promotes the activity of LH1 enzyme in HSF cells; in vitro, it increases the content of COLⅠ and COLⅢ and the activity of LH1 enzyme in the self-fermentation supernatant; oral administration of inactivated bacterial cells increases collagen content; oral administration of the self-fermentation supernatant increases the activity of LH1, P4H, and LOX enzymes, promotes collagen synthesis, and increases collagen content. Therefore, this *Bifidobacterium adolescentis* has great application potential in the preparation of oral drugs that promote host collagen synthesis, as well as in the preparation of food, health products, or cosmetics.

The application belongs to the technical field of microorganisms, and particularly relates to application of Bifidobacterium adolescentis in improving muscle mass. The Bifidobacterium adolescentis YBT652 provided in the application is screened from fecal samples of teenagers in Harbin region, and is verified to have good ability of improving muscle mass. The microgel preparation constructed by using the Bifidobacterium adolescentis YBT652 can not only effectively realize embedding of the Bifidobacterium adolescentis, but also can improve the anti-gastrointestinal digestion ability and the adhesion ability in the intestinal tract of the Bifidobacterium adolescentis. Especially, the application induces muscle mass attenuation and simulates the aging process by using d-galactose, reveals the significant effect of the microgel preparation of the Bifidobacterium adolescentis in improving muscle mass attenuation, can provide new ideas and methods for microbial treatment of muscle mass attenuation, and provides technical support and theoretical basis for development of new treatment drugs.